Market revenue in 2022 | USD 1,192.7 million |
Market revenue in 2030 | USD 1,911.3 million |
Growth rate | 6.1% (CAGR from 2022 to 2030) |
Largest segment | Estrogen and progesterone replacement therapy |
Fastest growing segment | Parathyroid Hormone replacement |
Historical data | 2018 - 2021 |
Base year | 2022 |
Forecast period | 2023 - 2030 |
Quantitative units | Revenue in USD million |
Market segmentation | Estrogen and Progesterone Replacement Therapy, HGH replacement therapy, Thryoid hormone replacement therapy, Testosterone Replacement Therapy, Parathyroid Hormone replacement |
Key market players worldwide | Eli Lilly and Co, Bayer AG, Hisamitsu Pharmaceutical Co Inc, Pfizer Inc, Merck & Co Inc, Viatris Inc, Novo Nordisk A/S ADR, AbbVie Inc, Roche Holding AG ADR, Ascend Wellness Holdings Inc |
No credit card required*
Name | Profile | # Employees | HQ | Website |
---|
The databook is designed to serve as a comprehensive guide to navigating this sector. The databook focuses on market statistics denoted in the form of revenue and y-o-y growth and CAGR across the globe and regions. A detailed competitive and opportunity analyses related to hormone replacement therapy market will help companies and investors design strategic landscapes.
Estrogen and progesterone replacement therapy was the largest segment with a revenue share of 53.41% in 2022. Horizon Databook has segmented the Japan hormone replacement therapy market based on estrogen and progesterone replacement therapy, hgh replacement therapy, thryoid hormone replacement therapy, testosterone replacement therapy, parathyroid hormone replacement covering the revenue growth of each sub-segment from 2018 to 2030.
In Japan, the market for hormone replacement therapy is growing over the forecast period due to the rising prevalence of conditions such as menopause & hypothyroidism. According to an article published in International Journal of Epidemiology, (February 2021), the percentage of women using hormone replacement therapy during the followup period, the proportion of hormone replacement therapy users who stopped the therapy before the baseline survey, the percentage of all participants who had used hormone replacement therapy for 2 years were 10.6%, 3.2%, and 13.8%, respectively.
Furthermore, according to the Japan Society of Obstetrics and Gynecology annual report (2021), hormone replacement therapy is used as a first-line treatment option in patients with surgical menopause. In addition, estrogen and progesterone replacement therapy are used to treat symptoms associated with menopause.
Horizon Databook provides a detailed overview of country-level data and insights on the Japan hormone replacement therapy market , including forecasts for subscribers. This country databook contains high-level insights into Japan hormone replacement therapy market from 2018 to 2030, including revenue numbers, major trends, and company profiles.
Sign up and get instant basic access to databook, upgrade
when ready, or enjoy our
free plan indefinitely.
Included in Horizon account